Weekly News

Valeant beats on earnings, cuts revenue forecast for the year

August 08,2017 13:08

Since taking the helm in April 2016, Joseph Papa has been trying to rebuild the company's business and regain investor confidence after a flurry of investigations into its accounting and pricing practices. One of Papa's biggest challenges has been to ...and more »



Valeant CEO Joseph PapaReuters

Canada's Valeant Pharmaceuticals International Inc cut its full-year revenue forecast, even as it reported a better-than-expected quarterly profit and said it expects to repay more than $5 billion in debt by February.
Since taking the helm in April 2016, Joseph Papa has been trying to rebuild the company's business and regain investor confidence after a flurry of investigations into its accounting and pricing practices.
One of Papa's biggest challenges has been to cut the company's towering debt, which ballooned to nearly $30 billion following a spate of deal-making under former CEO Mike Pearson.
The maker of Bausch + Lomb contact lenses said on Tuesday it now expects revenue of $8.70 billion to $8.90 billion for the full year, down from its previous forecast of $8.90 billion to $9.10 billion.
Last month, the drugmaker paid down $811 million of debt with proceeds from the sale of its cancer treatment unit Dendreon Pharmaceuticals, and agreed to sell its Obagi Medical Products business for $190 million. In June, Valeant agreed to sell its iNova Pharmaceuticals business for $930 million.
Valeant, which also maintained its 2017 forecast for adjusted earnings before interest, tax, depreciation and amortization, said it had long-term debt of about $28.5 billion as of June 30.
The company said it expected to pay down more than $5 billion in debt from divestiture proceeds and free cash flow before February 2018.
Excluding items, the Laval, Quebec-based company earned $1.05 per share, ahead of the average analyst estimate of 94 cents, according to Thomson Reuters I/B/E/S.
Revenue fell 7.8 percent to $2.23 billion in the second quarter ended June 30, hurt by declines in volume and pricing of its generic and neurology products.
Net loss attributable to Valeant narrowed to $38 million from $302 million, a year earlier. The decrease in net loss was mainly due to income tax gains and increase in operating income, the company said. (Reporting by Natalie Grover in Bengaluru; Editing by Saumyadeb Chakrabarty)
Read the original article on Reuters. Copyright 2017. Follow Reuters on Twitter.

SEE ALSO: This chart helps explain why financial markets are so quiet, and why they could stay that way

business cards business business casual business insider business letter format business plan template business plan business casual men business for sale business administration

Share this article

Related videos

Techtronic Industries CEO Says Very Confident About 2017
Techtronic Industries CEO Says Very Confident A...
IBM - After Hours Earnings Were a Big Miss on Lower Revenue Guidance
IBM - After Hours Earnings Were a Big Miss on L...

DON'T MISS THIS STORIES